Form 6-K GLAXOSMITHKLINE PLC For: Dec 08
FORM 6-K
�
�
SECURITIES AND EXCHANGE COMMISSION(
Washington D.C. 20549
�
�
Report of Foreign Issuer
�
�
Pursuant to Rule 13a-16 or 15d-16 of(
the Securities Exchange Act of 1934
�
�
�
For period ending�December 2014
�
GlaxoSmithKline plc
(Name of registrant)(
�
�
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)(
�
�
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F(
�
�
Form 20-F x��� �Form 40-F(
�
--(
�
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.(
�
�
Yes����� No x
--
�
�
�
�
�GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
�
�
In accordance with DTR 3.1.4 R(1)(c) GlaxoSmithKline plc (GSK) was advised on 8 December 2014 of the following increase in the notional allocation of GSK American Depositary Shares (ADSs) on 5 December 2014, at a price of $46.04 per ADS, following the revaluation of the cash element of the notional investment held within the GSK 401K plan:
�
�
�
�
Connected person
|
�
Number of ADSs
|
�
Dr K Slaoui
(Connected person of Dr M Slaoui)
|
�
2
|
�
�
V A Whyte
Company Secretary
�
8 December 2014
�
�
�
�
�
�
�
SIGNATURES
�
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.(
�
�
GlaxoSmithKline plc
(Registrant)(
Date:�December�08,�2014�
�
�
By:�VICTORIA WHYTE
----------------------
�
�
Victoria�Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GBank Financial Holdings Inc. Annual Meeting of Shareholders Scheduled for Tuesday, May 7th at 2:00 P.M. Pacific Time
- Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints
- Federal Home Loan Bank of New York Announces First Quarter 2024 Operating Highlights
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!